IRulya Therapeutics
IRLA----
Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: IRulya Therapeutics(IRLA) the EBIT is -79.78 M (-665.2%), Miss estimate;the EPS is -12.31 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.08B665.15%
-0.02B105.24%
-0.06B559.91%
EPSMiss expectations
-12.31--
-12.29--
-0.0200--%
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly